As of the latest Form 4 filed Jul 6, 2026.
What BridgeBio Oncology Therapeutics, Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 14 most recent filings for BBOT.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-01 | Chen Bihua Director | JOther | +131K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Chen Bihua, Director | JOther | +1.70M | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Chen Bihua, Director | JOther | +2.69M | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Chen Bihua, Director | JOther | −4.53M | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Cobo Marc Principal Accounting Officer | FTax | −125.00 | $7.80 | $975.00 | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Elmelech Idan COO & Principal Financial Ofcr | FTax | −343.00 | $7.80 | $2.68K | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Ben Yong Chief Med & Dev Officer | FTax | −1.05K | $7.80 | $8.17K | No | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Beltran Pedro President and CEO | FTax | −1.05K | $7.80 | $8.17K | No | Form 4 ↗ |
| 2026-05-05 | 2026-04-01 | Ben Yong Chief Med & Dev Officer | FTax | −1.05K | $9.03 | $9.45K | No | Form 4 ↗ |
| 2026-05-05 | 2026-04-01 | Beltran Pedro President and CEO | FTax | −1.05K | $9.03 | $9.45K | No | Form 4 ↗ |
| 2026-05-05 | 2026-04-01 | Mehra Uneek Insider | FTax | −524.00 | $9.03 | $4.73K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Mehra Uneek Chief Financial Officer | AAward | +23.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Beltran Pedro Chief Scientific Officer | AAward | +46.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Ben Yong Chief Med & Dev Officer | AAward | +46.7K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BBOT’s full analysis or the market-wide insider trading feed. The tabs above jump to BBOT’s other SEC data.
Source: SEC Form 4 filings for BBOT, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.